Bioheart and Airspeed Equity together have introduced MyoStim Lab Culture Stimulator, Limb Blood Flow Stimulator, Implantable Heart Pacemaker and the Biopace Biological Pacemaker.

Under the terms of the agreement, Airspeed Equity has license for these products with Bioheart.

Bioheart will receive milestone based cash payments as well as royalty payments on all net sales.

Airspeed Equity founder and MD Alan Remen said they’re excited about developing these four important and potentially life-saving products in San Diego, the heart of the biotechnology and healthcare community.

Bioheart co-founder and CTO Howard Leonhardt said the discovery that low voltage electrical stimulation of the heart can both regenerate damaged heart tissue and replace high voltage implantable defibrillators for arrhythmia fibrillation recovery may change the course of care for the more than 30 million patients suffering from heart failure.